The Nippon India Nifty Pharma ETF has outperformed major peers with a 17.9% return over the last six months. Investors should note this fund leads in multiple timeframes, though performance reflects specific sectoral trends in pharmaceutical stocks. Understanding the fund's strategy and its reliance on the Nifty Pharma index is essential for those tracking healthcare-focused investments.
Detailed Coverage
The Nippon India Nifty Pharma ETF has emerged as a top performer among large-scale index exchange-traded funds (ETFs) in India. Data tracked through July 22, 2026, shows the fund delivered a return of 17.9% over the past six months, surpassing other major index funds such as the HDFC Nifty Smallcap 250 ETF and the Mirae Asset Nifty Midcap 150 ETF.
Performance Across Timeframes
The fund’s strength extends beyond the six-month window. It has shown consistent gains, leading with a 4.1% return over the past month and 14.9% over the last three months. Longer-term data further highlights this trend, as the fund outperformed its benchmark index by 19.2 percentage points over the last year. While the benchmark Nifty Pharma index recorded a decline of 3.2% during that annual period, the ETF managed to deliver positive results. Over a three-year horizon, the fund recorded a 22.2% return, compared to the 8.0% return of its benchmark.
Understanding the Sector Context
It is important for investors to recognize that these returns are linked to the performance of the Nifty Pharma index, which tracks the largest pharmaceutical companies in India. The outperformance of the ETF relative to its benchmark often results from tracking differences and expense ratios, which are standard for passively managed funds. Unlike actively managed mutual funds where managers pick specific stocks to beat the market, an index ETF aims to replicate the performance of its underlying index. Investors should consider that the pharmaceutical sector is influenced by global demand, regulatory approvals from bodies like the US FDA, and raw material pricing. A sector-specific fund concentrates risk, meaning the performance is highly dependent on the health of the Indian pharma industry rather than a diversified market portfolio.
Important Considerations for Investors
When evaluating this fund, investors should look at its size and consistency. The Nippon India ETF Nifty Midcap 150 currently holds a larger asset base of ₹3,598.8 crore compared to the pharma-specific fund, which helps in managing liquidity for large transactions. Because this is a sector-specific investment, it can be more volatile than broad-market ETFs. The next monitorable for investors will be the fund’s expense ratio and its ability to maintain low tracking error—the difference between the fund’s performance and the actual index return—as market conditions change in the coming quarters.